Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $100.00 by Analysts at HC Wainwright

Structure Therapeutics (NASDAQ:GPCR) had its price target cut by HC Wainwright from $114.00 to $100.00 in a report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also weighed in on the company. Guggenheim lifted their price objective on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus lifted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Citizens Jmp dropped their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Finally, Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $106.50.

Structure Therapeutics Stock Performance

GPCR stock opened at $56.65 on Monday. The stock has a market capitalization of $4.01 billion, a PE ratio of -71.71 and a beta of -1.79. The company has a fifty day moving average of $73.33 and a 200-day moving average of $49.98. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley lifted its position in shares of Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the period. Wellington Management Group LLP grew its holdings in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after acquiring an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after acquiring an additional 1,381,745 shares during the period. Avoro Capital Advisors LLC increased its stake in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC purchased a new position in Structure Therapeutics in the 4th quarter valued at approximately $61,086,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: Positive Phase 2 ACCESS II topline data: ACCESS II showed placebo‑adjusted mean weight loss of 16.3% (~39 lbs) at 180 mg and 16.0% (~37 lbs) at 240 mg at 44 weeks, with no evidence of an early plateau — results the company says rank among the highest for oral GLP‑1s and are comparable to injectables. Press Release
• Positive Sentiment: Heavy media coverage highlights outsized efficacy vs. oral peers and potential market opportunity (reports cite up to ~16% weight loss / 39 lbs), driving investor excitement and secondary trading interest. Representative coverage: Investors Business Daily and Benzinga. Investors Article Benzinga Article
• Neutral Sentiment: Analyst update: HC Wainwright trimmed its price target from $114 to $100 but kept a “Buy” rating — still implies substantial upside from current levels, so the note is overall constructive despite the PT cut. Benzinga
• Negative Sentiment: Earlier financial performance: the company reported an EPS miss in its Feb 26 quarter (a negative reminder that GPCR remains pre‑commercial and will need further data, regulatory clarity, and capital to reach commercialization), which could temper longer‑term valuation until confirmatory trials and development milestones are delivered.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.